Sage Therapeutics (Sage Therapeutics) Cash Flow from Operations

: $-540.59 Mil (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Dec. 2023, Sage Therapeutics's Net Income From Continuing Operations was $-32.71 Mil. Its Depreciation, Depletion and Amortization was $0.41 Mil. Its Change In Working Capital was $-106.29 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $12.95 Mil. And its Cash Flow from Others was $6.12 Mil. In all, Sage Therapeutics's Cash Flow from Operations for the three months ended in Dec. 2023 was $-119.52 Mil.

Sage Therapeutics Cash Flow from Operations Historical Data

The historical data trend for Sage Therapeutics's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Operations

-528.71

664.28

-378.18

-460.04

-540.59

Sage Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash Flow from Operations																-126.93	-153.68	-131.52	-135.87	-119.52

Sage Therapeutics Cash Flow from Operations Calculation

Sage Therapeutics's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

	Cash Flow from Operations		(A: Dec. 2023 )
=	Net Income From Continuing Operations	+	Depreciation, Depletion and Amortization	+	Change In Working Capital	+	Deferred Tax
=	-541.489	+	1.393	+	-67.384	+	0
+	Cash from Discontinued Operating Activities	+	Asset Impairment Charge	+	Stock Based Compensation	+	Cash Flow from Others
+	0	+	0	+	73.37	+	-6.475
=	-540.59

Sage Therapeutics's Cash Flow from Operations for the quarter that ended in Dec. 2023 is:

	Cash Flow from Operations		(Q: Dec. 2023 )
=	Net Income From Continuing Operations	+	Depreciation, Depletion and Amortization	+	Change In Working Capital	+	Deferred Tax
=	-32.706	+	0.409	+	-106.287	+	0
+	Cash from Discontinued Operating Activities	+	Asset Impairment Charge	+	Stock Based Compensation	+	Cash Flow from Others
+	0	+	0	+	12.95	+	6.115
=	-119.52

Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-540.59 Mil.

Sage Therapeutics (NAS:SAGE) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Sage Therapeutics's net income from continuing operations for the three months ended in Dec. 2023 was $-32.71 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Sage Therapeutics's depreciation, depletion and amortization for the three months ended in Dec. 2023 was $0.41 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Sage Therapeutics's change in working capital for the three months ended in Dec. 2023 was $-106.29 Mil. It means Sage Therapeutics's working capital declined by $106.29 Mil from Sep. 2023 to Dec. 2023 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Sage Therapeutics's cash flow from deferred tax for the three months ended in Dec. 2023 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Sage Therapeutics's cash from discontinued operating Activities for the three months ended in Dec. 2023 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Sage Therapeutics's asset impairment charge for the three months ended in Dec. 2023 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Sage Therapeutics's stock based compensation for the three months ended in Dec. 2023 was $12.95 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Sage Therapeutics's cash flow from others for the three months ended in Dec. 2023 was $6.12 Mil.

Sage Therapeutics Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Sage Therapeutics's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.

Sage Therapeutics (Sage Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (NAS:SAGE) » Definitions » Cash Flow from Operations

Comparable Companies

Traded in Other Exchanges

SG7:Germany SG7:Germany

Address

215 First Street, Cambridge, MA, USA, 02142

Website

https://www.sagerx.com

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.

Executives

Elizabeth Barrett	director	C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Jessica Federer	director	C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Jeffrey M Jonas	director, officer: See Remarks	ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Barry E Greene	director	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Laura Gault	officer: Chief Medical Officer	C/O SAGE THERAPEUTICS, INC., 245 FIRST STREET, SUITE 16, CAMBRIDGE MA 02142
George Golumbeski	director	C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Christopher Benecchi	officer: Chief Commercial Officer	C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
James M Frates	director	88 SIDNEY ST, CAMBRIDGE MA 021394136
Biogen Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Biogen Ma Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Albert Robichaud	officer: Chief Scientific Officer	215 FIRST STREET, CAMBRIDGE MA 02142
Michael Cloonan	officer: Chief Business Officer	C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Anne Marie Cook	officer: General Counsel	101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Steven M Paul	director	C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285
Kimi Iguchi	officer: See Remarks	100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035